Long-term survival of low- and intermediate risk TAVI-patients: a real world, single center comparison of 684 patients treated with the sapien 3 or the sapien XT device.

Back

ESC Premium Access

Long-term survival of low- and intermediate risk TAVI-patients: a real world, single center comparison of 684 patients treated with the sapien 3 or the sapien XT device.

Session: Poster session 1 - Risk stratification and prognosis after TAVI

Topic: Aortic valve disease

Speaker: Mr J. Vendrik (Amsterdam, NL)

Event: ESC Congress 2017

Congress Presentation

About the speaker

Mr Jeroen Vendrik

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

0 follower

10 more presentations in this session

Effect of transcatheter aortic valve implantation (TAVI) in acquired von Willebrand syndrome and molecular analysis of high-molecular-weight multimers.

Speaker: Doctor M. Perrone (Rome, IT)

Access

Combination of pre-existing atrial fibrillation and coronary artery disease associates with poor outcome in patients who undergo TAVI

Speaker: Doctor H. Hioki (Tokyo, JP)

Access

Abstract

Slides

Transcatheter aortic valve replacement alters expression levels of circulating myocardial microRNAs

Speaker: Doctor F. Jansen (Bonn, DE)

Access

Abstract

Slides

Cardiac biomarkers and clinical scores for risk stratification in patients with severe symptomatic aortic stenosis undergoing TAVI. Which ranks first now?

Speaker: Mrs A. Stundl (Bonn, DE)

Access

Abstract

Slides

Peri-procedural myocardial injury depends on transcatheter heart valve type but does not predict mortality in patients after tavi

Speaker: Mrs A. Stundl (Bonn, DE)

Access

Abstract

Slides

Access the full session

Poster session 1 - Risk stratification and prognosis after TAVI

Speakers: Mr J. Vendrik, Doctor M. Perrone, Doctor H. Hioki, Doctor F. Jansen, Mrs A. Stundl...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

Long-term survival of low- and intermediate risk TAVI-patients: a real world, single center comparison of 684 patients treated with the sapien 3 or the sapien XT device.

About the speaker

Mr Jeroen Vendrik

10 more presentations in this session

Effect of transcatheter aortic valve implantation (TAVI) in acquired von Willebrand syndrome and molecular analysis of high-molecular-weight multimers.

Combination of pre-existing atrial fibrillation and coronary artery disease associates with poor outcome in patients who undergo TAVI

Transcatheter aortic valve replacement alters expression levels of circulating myocardial microRNAs

Cardiac biomarkers and clinical scores for risk stratification in patients with severe symptomatic aortic stenosis undergoing TAVI. Which ranks first now?

Peri-procedural myocardial injury depends on transcatheter heart valve type but does not predict mortality in patients after tavi

Access the full session

Poster session 1 - Risk stratification and prognosis after TAVI

About the event

ESC Congress 2017

ESC 365 is supported by